Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

The belief that AAV gene therapies are not commercially viable is a myth. Attend this webinar for data on therapeutic pipeline breakthroughs, novel technologies, and clinical and manufacturing strategies designed to transform the treatment of cardiometabolic and age-related diseases via the application of AAV-based gene therapies.

Dan Oliver, CEO of Rejuvenate Bio, will provide key updates on the company’s groundbreaking pipeline, including RJB-0402, a liver-directed gene therapy designed for cardiac indications such as Desmoplakin Arrhythmogenic Cardiomyopathy (ACM) and metabolic disorders like obesity in GLP-1 non-responders. He will also discuss their animal health portfolio, featuring RJB-01 for Mitral Valve Disease, obesity/diabetes, and kidney failure in dogs, as well as RJB-02 for canine osteoarthritis. Dan will outline the CMC and business strategies ensuring these therapies reach commercial success.

Following Dan’s presentation, Ji Hyun “Jackie” Lee from WuXi Advanced Therapies’ Process Development team will introduce a novel platform enhancing AAV production efficiency while reducing costs. Jackie will explain how TESSA® (Tetracycline-Enabled Self-Silencing Adenovirus) technology can help to optimize AAV manufacturing by improving yield, packaging efficiency, and contaminant-free scalability. Don’t miss this deep dive into the future of commercially viable AAV gene therapies.

AAV gene therapies are commercially viable: Learn how single-administration AAV gene therapies can effectively and profitably address cardiometabolic and age-related diseases.
Pipeline breakthroughs in human and animal health: Gain insights into Rejuvenate Bio’s RJB-0402 for cardiac and metabolic conditions, as well as RJB-01 and RJB-02 for treating serious diseases in dogs.
Strategic approaches to clinical and manufacturing success: Understand the key clinical, CMC, and business strategies driving AAV therapeutics toward commercialization.
Improving AAV production: Explore avenues for reducing COGs and increasing yield, enhancing packaging efficiency, and minimizing contaminants

Dan Oliver

CEO, Co-Founder at Rejuvenate Bio

Daniel Oliver is a co-founder and the CEO of Rejuvenate Bio, a spinout of George Church’s Lab at Harvard Medical School working on targeting the driver of age-related disease through the use of novel gene therapies. Rejuvenate Bio is Prior to Rejuvenate Bio, Daniel was awarded a Blavatnik Fellowship during which he co-founded Voxel8. Voxel8 was named one of the top 9 innovations at CES and one of the top 50 most innovative companies by the MIT Technology Review. Daniel received his M.B.A. from Harvard Business School and has degrees in Mechanical Engineering and Business from the California Institute of Technology.

Ji Hyun Lee

Scientist at WuXi Advanced Therapies

Ji Hyun “Jackie” Lee is a Process Development Scientist with WuXi Advanced Therapies. She joined the organization in 2020 and specializes in downstream purification with an exclusive focus on viral vectors including AAV and LVV. She earned her degree from Temple University with a major in Biochemistry.

in 4

Days